Goldman Sachs tips ResMed shares to rocket 30% to a record high
The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...
Goldman Sachs starts coverage on ResMed with "buy" rating
Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
ResMed initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...
Harvard Business Review3d
How Generative AI Improves Supply Chain Management
The Problem Despite advances in digitizing supply chain management and making data-driven decisions, business planners and executives still expend significant time and effort on understanding ...
Balanced Outlook on ResMed: Strong Execution and Innovations Offset by Valuation Concerns and Market Challenges
Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...
Future Market Insights12d
Global Continuous Positive Airway Pressure (CPAP) Market Poised for Sustained Growth, Reaching USD 900 Million by 2033 rise at a CAGR of 6%
The global continuous positive airway pressure (CPAP) market is projected to reach a value of USD 900 million by 2033, ...
theregister20d
It's only a matter of time before LLMs jump start supply-chain attacks
Interview Now that criminals have realized there's no need to train their own LLMs for any nefarious purposes - it's much cheaper and easier to steal credentials and then jailbreak existing ones - the ...